Chiron ends clinical trial of HIV treatment
BY Advocate.com Editors
October 25 2002 12:00 AM ET
Chiron Corp. announced Wednesday that it is ending the development of three compounds, including a recombinant form of interleukin-2 being studied in a Phase III trial for the treatment of patients with HIV. The company had been expected to complete the clinical trial, including patient follow-up, in 2007. Chiron is now reviewing data for a possible regulatory submission for approval of IL-2 only in a small subset of HIV-positive patients who do not receive any response to other anti-HIV medications. The company also stopped development of compounds intended to treat cystic fibrosis and hepatitis B.
- The Top 175 Essential Films of All Time for LGBT Viewers
- Leslie Jordan Banishes Antigay Starbucks Patrons: 'Get Out of My House!'
- Living Trans, From Iran to New York City
- I Am Jazz: 14, Transgender, and the Star of My Own Docu-series
- Op-ed: The Far-Reaching Consequences of Dating App Racism
- White House to Unveil New HIV Strategy